
Nancy Bitar
Examiner (ID: 11522, Phone: (571)270-1041 , Office: P/2669 )
| Most Active Art Unit | 2664 |
| Art Unit(s) | 2624, 2669, 2664 |
| Total Applications | 1250 |
| Issued Applications | 1011 |
| Pending Applications | 68 |
| Abandoned Applications | 193 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18537784
[patent_doc_number] => 20230242884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => COMPOSITIONS AND METHODS FOR ENGRAFTMENT OF BASE EDITED CELLS
[patent_app_type] => utility
[patent_app_number] => 17/799159
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 98307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799159
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/799159 | COMPOSITIONS AND METHODS FOR ENGRAFTMENT OF BASE EDITED CELLS | Feb 11, 2021 | Pending |
Array
(
[id] => 18207887
[patent_doc_number] => 20230054144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDER
[patent_app_type] => utility
[patent_app_number] => 17/796064
[patent_app_country] => US
[patent_app_date] => 2021-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796064
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/796064 | GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDER | Feb 10, 2021 | Pending |
Array
(
[id] => 18886432
[patent_doc_number] => 11865188
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-09
[patent_title] => Gene therapy for AADC deficiency
[patent_app_type] => utility
[patent_app_number] => 17/157745
[patent_app_country] => US
[patent_app_date] => 2021-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 18844
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157745
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/157745 | Gene therapy for AADC deficiency | Jan 24, 2021 | Issued |
Array
(
[id] => 18241223
[patent_doc_number] => 20230073534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => MODULATING TLR/NF-KB AND P53 SIGNALING PATHWAYS TO ENHANCE INTERSPECIES CHIMERISM BETWEEN EVOLUTIONARYILY DISTANT SPECIES
[patent_app_type] => utility
[patent_app_number] => 17/793150
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21474
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793150
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793150 | MODULATING TLR/NF-KB AND P53 SIGNALING PATHWAYS TO ENHANCE INTERSPECIES CHIMERISM BETWEEN EVOLUTIONARYILY DISTANT SPECIES | Jan 20, 2021 | Pending |
Array
(
[id] => 16870428
[patent_doc_number] => 20210163895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/146200
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40735
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17146200
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/146200 | Enhanced immune effector cells and use thereof | Jan 10, 2021 | Issued |
Array
(
[id] => 18213712
[patent_doc_number] => 20230059978
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/791106
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20739
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -69
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791106
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791106 | LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS | Jan 7, 2021 | Pending |
Array
(
[id] => 18210399
[patent_doc_number] => 20230056661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => METHODS AND COMPOSITIONS FOR PRODUCTION OF XENOGENEIC ISLET CELLS AND TREATMENT OF INSULIN-RESISTANT OR -DEFICIENT CONDITIONS WITH THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/790797
[patent_app_country] => US
[patent_app_date] => 2021-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13211
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17790797
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/790797 | METHODS AND COMPOSITIONS FOR PRODUCTION OF XENOGENEIC ISLET CELLS AND TREATMENT OF INSULIN-RESISTANT OR -DEFICIENT CONDITIONS WITH THE SAME | Jan 6, 2021 | Pending |
Array
(
[id] => 18193149
[patent_doc_number] => 20230046668
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => TARGETED INTEGRATION IN MAMMALIAN SEQUENCES ENHANCING GENE EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/788548
[patent_app_country] => US
[patent_app_date] => 2020-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788548
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/788548 | TARGETED INTEGRATION IN MAMMALIAN SEQUENCES ENHANCING GENE EXPRESSION | Dec 23, 2020 | Pending |
Array
(
[id] => 18497670
[patent_doc_number] => 20230220337
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => METHOD OF MICROGLIA DIFFERENTIATION CAPABLE OF SECURING LARGE QUANTITY OF MICROGLIA BY USING 3D ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 17/786483
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9233
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786483
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/786483 | METHOD OF MICROGLIA DIFFERENTIATION CAPABLE OF SECURING LARGE QUANTITY OF MICROGLIA BY USING 3D ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Dec 16, 2020 | Pending |
Array
(
[id] => 16899075
[patent_doc_number] => 20210177991
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => FRATAXIN EXPRESSION CONSTRUCTS
[patent_app_type] => utility
[patent_app_number] => 17/125449
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34213
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125449
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/125449 | Frataxin expression constructs | Dec 16, 2020 | Issued |
Array
(
[id] => 16882859
[patent_doc_number] => 20210169054
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => HUMANIZED HEART MUSCLE
[patent_app_type] => utility
[patent_app_number] => 17/118981
[patent_app_country] => US
[patent_app_date] => 2020-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12491
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118981
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/118981 | HUMANIZED HEART MUSCLE | Dec 10, 2020 | Abandoned |
Array
(
[id] => 16912898
[patent_doc_number] => 20210185990
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => NON-MEIOTIC ALLELE INTROGRESSION
[patent_app_type] => utility
[patent_app_number] => 17/118064
[patent_app_country] => US
[patent_app_date] => 2020-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73444
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118064
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/118064 | NON-MEIOTIC ALLELE INTROGRESSION | Dec 9, 2020 | Abandoned |
Array
(
[id] => 19439353
[patent_doc_number] => 12089574
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Humanized skeletal muscle
[patent_app_type] => utility
[patent_app_number] => 16/952807
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 14
[patent_no_of_words] => 11361
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952807
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/952807 | Humanized skeletal muscle | Nov 18, 2020 | Issued |
Array
(
[id] => 18497683
[patent_doc_number] => 20230220352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => METHOD FOR DIRECT TRANSDIFFERENTIATION OF SOMATIC CELL
[patent_app_type] => utility
[patent_app_number] => 17/776100
[patent_app_country] => US
[patent_app_date] => 2020-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776100
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/776100 | METHOD FOR DIRECT TRANSDIFFERENTIATION OF SOMATIC CELL | Nov 11, 2020 | Pending |
Array
(
[id] => 18036512
[patent_doc_number] => 20220380727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => GENERATION OF ENGINEERED REGULATORY T CELLS
[patent_app_type] => utility
[patent_app_number] => 17/775016
[patent_app_country] => US
[patent_app_date] => 2020-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12190
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775016
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/775016 | GENERATION OF ENGINEERED REGULATORY T CELLS | Nov 8, 2020 | Pending |
Array
(
[id] => 16686871
[patent_doc_number] => 20210069346
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain Injuries
[patent_app_type] => utility
[patent_app_number] => 17/091203
[patent_app_country] => US
[patent_app_date] => 2020-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5669
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091203
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/091203 | Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain Injuries | Nov 5, 2020 | Abandoned |
Array
(
[id] => 16778032
[patent_doc_number] => 20210115110
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
[patent_app_type] => utility
[patent_app_number] => 17/086072
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41890
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17086072
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/086072 | Method of producing recombinant high molecular weight vWF in cell culture | Oct 29, 2020 | Issued |
Array
(
[id] => 18056476
[patent_doc_number] => 20220387562
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/771627
[patent_app_country] => US
[patent_app_date] => 2020-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41352
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -237
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771627
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/771627 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISORDERS | Oct 22, 2020 | Pending |
Array
(
[id] => 18003638
[patent_doc_number] => 20220362404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => MODULATION OF CELLULAR VIABILITY
[patent_app_type] => utility
[patent_app_number] => 17/754597
[patent_app_country] => US
[patent_app_date] => 2020-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30990
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754597
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/754597 | MODULATION OF CELLULAR VIABILITY | Oct 20, 2020 | Pending |
Array
(
[id] => 16614031
[patent_doc_number] => 20210032684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => STABILIZATION OF NON-DENATURED POLYPEPTIDES, NUCLEIC ACIDS, AND EXOSOMES IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES
[patent_app_type] => utility
[patent_app_number] => 17/073580
[patent_app_country] => US
[patent_app_date] => 2020-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13263
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17073580
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/073580 | STABILIZATION OF NON-DENATURED POLYPEPTIDES, NUCLEIC ACIDS, AND EXOSOMES IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES | Oct 18, 2020 | Pending |